Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03975829 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pediatric Long-Term Follow-up and Rollover Study

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 63 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Study sites: 55 to 54v63
  2. Site details revised at 1 of 55 sitesv62
  3. Enrollment target: 165 to 163v61
  4. 2 versions Re-verified since Jun 25, 2026, no change to tracked fieldsv59-v60
  5. Trial status changed: Recruiting → Active, Not Recruiting Site details revised at 55 of 55 sitesv58 Show 1 more changeShow less
    • Site details revised at 55 of 55 sites
Show 3 earlier versionsHide 3 earlier versions
  1. Site details revised at 1 of 55 sitesv57
  2. Site details revised at 3 of 55 sitesv56
  3. Site details revised at 1 of 55 sitesv55
  1. Trial status changed: Active, Not Recruiting → Recruiting Enrollment target: 163 to 165 · Site details revised at 55 of 55 sitesv54 Show 2 more changesShow less
    • Enrollment target: 163 to 165
    • Site details revised at 55 of 55 sites
  2. Site details revised at 1 of 55 sitesv53
  3. Re-verified, no change to tracked fieldsv52
  4. Primary and study completion dates: Nov 6, 2026 to Nov 5, 2026v51
  5. Enrollment target: 165 to 163v50
  6. Primary completion date: Jun 23, 2026 to Nov 6, 2026v49
  7. Enrollment target: 163 to 165v48
  8. Enrollment target: 165 to 163v47
  9. 2 versions Re-verified since Jan 26, 2026, no change to tracked fieldsv45-v46
  10. Trial status: Recruiting to Active, Not Recruiting Site details revised at 55 of 55 sitesv44 Show 1 more changeShow less
    • Site details revised at 55 of 55 sites
  11. Trial status: Active, Not Recruiting to Recruiting Enrollment target: 163 to 165 · Completion date: Jul 23, 2026 to Nov 6, 2026 · Site details revised at 55 of 55 sitesv43 Show 3 more changesShow less
    • Enrollment target: 163 to 165
    • Completion date: Jul 23, 2026 to Nov 6, 2026
    • Site details revised at 55 of 55 sites
  12. Site details revised at 3 of 55 sitesv42
  13. Study sites: 54 to 55v41
  14. Study sites: 55 to 54v40
  15. Study sites: 54 to 55v39
  16. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 250 to confirmed 163 · Site details revised at 54 of 54 sitesv38 Show 2 more changesShow less
    • Enrollment target: estimated 250 to confirmed 163
    • Site details revised at 54 of 54 sites
  17. Trial status: Active, Not Recruiting to Recruiting Enrollment target: 163 to 250 · Primary completion date: May 29, 2026 to Jun 23, 2026 · Completion date: Jul 22, 2026 to Jul 23, 2026 · 1 morev37 Show 4 more changesShow less
    • Enrollment target: 163 to 250
    • Primary completion date: May 29, 2026 to Jun 23, 2026
    • Completion date: Jul 22, 2026 to Jul 23, 2026
    • Site details revised at 54 of 54 sites
  18. Study sites: 53 to 54v36
  19. Enrollment target: 164 to 163 Study sites: 54 to 53 · Primary completion date: Jul 22, 2026 to May 29, 2026v35 Show 2 more changesShow less
    • Study sites: 54 to 53
    • Primary completion date: Jul 22, 2026 to May 29, 2026
  20. Enrollment target: 165 to 164 Primary and study completion dates: May 29, 2026 to Jul 22, 2026v34 Show 1 more changeShow less
    • Primary and study completion dates: May 29, 2026 to Jul 22, 2026
  21. Enrollment target: 166 to 165v33
  22. Study sites: 53 to 54v32
  23. Study sites revised (53)v31 See this version in full on ClinicalTrials.gov ↗
  24. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 250 to confirmed 166 · Study sites: 54 to 53v30 Show 2 more changesShow less
    • Enrollment target: estimated 250 to confirmed 166
    • Study sites: 54 to 53
  25. Site details revised at 1 of 54 sitesv29
  26. Study sites revised (54)v28 See this version in full on ClinicalTrials.gov ↗
  27. Study sites: 53 to 54v27
  28. Study sites: 52 to 53 Completion date: Jul 20, 2026 to May 29, 2026v26 Show 1 more changeShow less
    • Completion date: Jul 20, 2026 to May 29, 2026
  29. Site details revised at 6 of 52 sitesv25
  30. Site details revised at 5 of 52 sitesv24
  31. Site details revised at 1 of 52 sitesv23
  32. Site details revised at 4 of 52 sitesv22
  33. Study sites revised (52)v21 See this version in full on ClinicalTrials.gov ↗
  34. Site details revised at 5 of 52 sitesv20
  35. Site details revised at 5 of 52 sitesv19
  36. Study sites: 50 to 52v18
  37. Study sites: 27 to 50v17
  38. Study sites: 18 to 27v16
  39. Site details revised at 1 of 18 sitesv15
  40. Study sites: 17 to 18 Completion date: May 29, 2026 to Jul 20, 2026v14 Show 1 more changeShow less
    • Completion date: May 29, 2026 to Jul 20, 2026
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Glioblastoma
670 trials monitored
See 44 trials at risk
Glioma
668 trials monitored
See 40 trials at risk
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Trial Details
NCT Number NCT03975829
Lead Sponsor Novartis Pharmaceuticals
Conditions Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma +15 more
Enrollment 163 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov